PRZOOM - /newswire/ -
Leuven, Belgium, 2012/01/26 - Pepric, a spin-off of imec, successfully concluded a EURO 1.4 million capital round - Pepric.com / imec.be.
This financial injection will be used for the commercialization of Pepric’s ex-vivo molecular analysis tool and the development of the following generation of in-vivo imagers.
Pepric (pepric.com) develops and commercializes equipment for quantitative detection of magnetically labeled cells, drugs and biomolecules. Quantification is often difficult for slow biological processes such as cell migration. Pepric’s sensitive tools will allow pre-clinical centres to evaluate the efficacy of new therapies, to perform an early diagnosis and to determine the biodistribution and pharmacokinetics of newly developed magnetic contrast agents.
The investment will support the production and commercialization of Pepric’s first product, the ex-vivo analysis tool for quantitative molecular and cellular detection. Furthermore it will enable Pepric to develop its core technology towards in-vivo detection and imaging. For this purpose the team will be reinforced with three additional employees.
With this financing round the Flemish investment company PMV also partakes in the Pepric story. That happens with means from the SOFI-Fund which has been created to support spin-offs from the four Flemish Strategic Research Centres (IBBT, imec, VIB en VITO). The initiative has been launched by the Flemish minister for Innovation, Mrs. Ingrid Lieten, and is managed by PMV. Also FIDIMEC, the spin-off investment vehicle of imec, participated in this round.
About PMV and SOFI
PMV (pmv.eu) is a Flemish investment company. It finances promising entrepreneurs from the very start through the growth and to the internationalisation of their business. It also invests in large infrastructure projects.
Its focus lies on the sustainable economic development of Flanders, with demonstrable added value for both economy and society.
As an experienced investment company, PMV also manages the SOFI-fund. That is an initiative created the Flemish government that provides 10 million euros of risk capital to spin-offs from the four Flemish Strategic Research Centres (IBBT, imec, VIB en VITO).
Imec (imec.be) performs world-leading research in nano-electronics. Imec leverages its scientific knowledge with the innovative power of its global partnerships in ICT, healthcare and energy. Imec delivers industry-relevant technology solutions. In a unique high-tech environment, its international top talent is committed to providing the building blocks for a better life in a sustainable society.
Imec is headquartered in Leuven, Belgium, and has offices in Belgium, the Netherlands, Taiwan, USA, China and Japan. Its staff of about 1,900 people includes more than 500 industrial residents and guest researchers. In 2010, imec's revenue (P&L) was 285 million euro.
Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a "stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Government), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre which is supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.) and imec China (IMEC Microelectronics (Shangai) Co., Ltd).
FIDIMEC NV is the investment vehicle of imec supporting the creation and growth of its spin-off companies. It is FIDIMEC’s mission to enable the growth of the startup from the earliest phase on to become a successful company.
Stephanie Teughels - CEO
Kapeldreef 75, B-3001 Leuven
T: +32 16 28 82 82 / E: stephanie.teughels[.]pepric.com.